What are the main indications for Vepotolizumab/Urova?

Polatuzumab/Polatuzumab is an innovative antibody-drug conjugate used to treat diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). Its main indication is the treatment of adult patients with DLBCL who have received at least two previous systemic therapies but are still relapsed or refractory. The drug was developed by Genentech (Roche) and was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2019, becoming the first ADC drug targeting CD79b.

The therapeutic logic of vepotuzumab is to accurately recognize the CD79b antigen on the surface of tumor cells through the antibody, and deliver the connected cytotoxic MMAE into the interior of the cancer cells, thereby inducing the destruction of the cell microtubule structure and triggering cell death. This mechanism of action is different from the non-selective toxicity of traditional chemotherapy and is more targeted and safer. Because DLBCL is a highly heterogeneous hematological tumor that often carries the risk of drug resistance or recurrence, the advent of vepotuzumab provides a new treatment option for patients who have failed multiple lines of treatment.

Clinical studies have shown that the triple regimen of vepotuzumab, bendamustine, and rituximab has significant clinical advantages in relapsed and refractory DLBCL, which can significantly improve the complete remission rate and prolong overall survival. In addition, overseas countries are also actively exploring its application potential in treatment-naïve populations and other B-cell lymphomas (such as follicular lymphoma) recently. With the clinical success of more ADC drugs, the indications of velpotuzumab are expected to gradually expand to a wider range of B cell malignancies.

Overall, the launch of vepotuzumab marks a new stage of precision and immune integration in the treatment of hematological tumors, providing new hope for patients who are ineffective or intolerant to traditional chemotherapy. Its scientific and clinical value has been widely recognized by the international academic community.

Reference materials:https://www.drugs.com/polivy.html